CorMedix Therapeutics (CRMD) said Monday that its Board has approved a share repurchase program of up to $75 million through December 31, 2027.
"With a strong balance sheet, solid operating performance, and expected ongoing cash flow generation, we believe we are well positioned to execute this share repurchase program while continuing to advance our growth strategy," said Joseph Todisco, Chairman & CEO of CorMedix Therapeutics.
The company expects to begin repurchasing shares as early as the first quarter of 2026.
As of December 31, 2025, CorMedix had approximately $150 million in cash and cash equivalents and 79.3 million shares outstanding.
CorMedix shares were up more than 2% in pre-market trading after closing at $7.76, up 3.24% on Friday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.